Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study

Table 5 Drug Susceptibility Profiles of patients with HIV Drug Resistance Mutations Detected

Patient No.	Regimen	Drug Resistance Mutation Types			Susceptibility to 1 L Drugs									Susceptibility to 2 L Drugs			2 L GSS	Subtype
Patient No.	Regimen	NRTIs	NNRTIs	PIs	ABC	AZT	FTC	3TC	TDF	EFV	ETR	NVP	RPV	DRV/r	ATV/r	LPV/r	2 L GSS	Subtype
1	^bOthers/FTC/NVP	None	V90I	K20I	S	S	^aS	S	^aS	S	S	^aS	S	S	S	S	3.0	02_AG
2	TDF/FTC/NVP	None	V90IV	K20I	S	S	^aS	S	^aS	S	S	^aS	S	S	S	S	3.0	02_AG
3	AZT/3TC/EFV	None	None	M46 L, K20I	S	^aS	S	^aS	S	^aS	S	S	S	S	S	S	2.75	G
4	^#Others/3TC/EFV	None	None	L10I, L23IL	S	^aS	S	^aS	S	*S	S	S	S	S	S	S	3.0	A1
5	AZT/3TC/NVP	None	E138EG	None	S	^aS	S	^aS	S	S	S	*S	L	S	S	S	3.0	C
6	TDF/FTC/EFV	None	K103Q, E138AE	K20I	S	S	^aS	S	^aS	^aS	S	S	L	S	S	S	3.0	G
7	AZT/3TC/NVP	None	V90IV, V108IV	None	S	^aS	S	^aS	S	S	S	^aL	S	S	S	S	3.0	J
8	AZT/3TC/NVP	None	V108I	K20I	S	^aS	S	^aS	S	S	S	^aL	S	S	S	S	3.0	G
9	AZT/3TC/EFV	None	K103 N	K20I	S	^aS	S	^aS	S	^aH	S	H	S	S	S	S	3.0	G
10	AZT/3TC/EFV	None	V106A, F227 L	K20I	S	^aS	S	^aS	S	^aH	S	H	S	S	S	S	3.0	02_AG
11	^bOthers/FTC/NVP	None	K103KN	K20I	S	S	^aS	S	^aS	H	S	^aH	S	S	S	S	3.0	02_AG
12	TDF/FTC/NVP	None	V90I, K103 N	K20I	S	S	^aS	S	^aS	H	S	^aH	S	S	S	S	3.0	02_AG
13	AZT/3TC/NVP	M184 V	K103 N, E138A	K20I	L	^aS	H	^aH	S	H	S	^aH	L	S	S	S	2.0	G
14	AZT/3TC/EFV	D67DN, K70R, M184 V, K219E	K103 N, V108I	K20I	L	^aL	H	^aH	L	^aH	S	H	S	S	S	S	1.5	02_AG
15	TDF/3TC/EFV	K70E, M184 V	K103 N, V108I, H221Y	L10I, K20I	L	S	H	^aH	^aL	^aH	S	H	S	S	S	S	2.0	02_AG
16	AZT/3TC/NVP	M184 V	A98AG, K101E, Y181C	K20I	L	^aS	H	^aH	S	L	L	^aH	H	S	S	S	2.0	02_AG

S Susceptible and Potential low-level resistance, L Low-level resistance and Intermediate-level resistance, H High-level resistance. NRTIs Nucleoside Reverse Transcriptase Inhibitors, NNRTIs Non-Nucleoside Reverse Transcriptase Inhibitors, PIs Protease Inhibitors; 1 L-First-line; 2 L = Second-line: GSS Genotype Sensitivity Score. ^aIndicate drugs in patient’s First-line regimen; ^bOthers = Backbone NRTI was switched

ISSN: 1471-2180